# Official Website: SymbioCellTech

**Type:** source
**Status:** Useful
**Confidence:** Medium
**Source Type:** Official Website
**URL:** https://symbiocelltech.com/
**Publisher:** SymbioCellTech, LLC
**Accessed:** 2026-06-19
**Updated:** 2026-06-19

## Summary

SymbioCellTech's official website describes Neo-Islets, a patented stem-cell-enabled cell therapy intended to functionally cure Type 1 diabetes without systemic immunosuppression. The company states it won the American Diabetes Association's Innovation Challenge Award in 2024 and is developing an outpatient abdominal-cavity administration approach using co-clustered pancreatic beta cells and mesenchymal stem cells (MSCs).

## Useful Claims

- Mission statement: free the 16 million people with Type 1 diabetes from daily insulin injections and diabetes-associated complications without relying on potentially harmful anti-rejection drugs.
- Neo-Islets are three-dimensional clusters combining culture-expanded insulin-expressing cells with high numbers of MSCs, designed to provide "natural encapsulation" rather than foreign-device encapsulation.
- When administered into the abdominal cavity, Neo-Islets are described as engrafting in the omentum, providing physiologically regulated insulin secretion, achieving euglycemia, and offering immune isolation from destructive immunosurveillance.
- The technology page states Neo-Islets address both autoimmune destruction of beta cells and allo-immune rejection of donor islets without systemic immunosuppression.
- Donor-scarcity claim: approximately 80 doses of human Neo-Islets can be created from a single pancreas donor, with further optimization possible.
- Vascularization: MSC component is described as promoting neo-vascularization to supply transplanted insulin-producing cells.
- Insulin delivery: Neo-Islets in the omentum release insulin into blood supply that flows directly into the hepatic portal system, mimicking physiologic pancreatic delivery rather than subcutaneous injection.
- Preclinical claims: functional cure of Type 1 diabetes in preclinical studies; canine clinical trial with up to 50% reduction in insulin need and ~100 mg/dL blood glucose reduction sustained over 15+ months.
- The site references a July 2017 *Stem Cells Translational Medicine* cover-feature publication and links to additional technical materials.
- Website states SCT is "aiming to begin Phase I, human clinical trials in 2023" — a date that may be stale relative to current regulatory status.
- 2024 ADA Innovation Challenge Award winner is prominently displayed on the homepage.

## Reliability Notes

This is an official company source. Claims of functional cure, immune isolation without immunosuppression, and durable engraftment are the core scientific thesis and remain preclinical leads until validated in controlled human trials. The Phase I 2023 timeline on the technology page conflicts with other public materials and should not be treated as current without FDA filing confirmation. Clinical performance, safety, and manufacturing scale should be verified against peer-reviewed publications (e.g., PLOS ONE, *Stem Cells Translational Medicine*), FDA correspondence, and independent press before high-confidence use.

## Related Pages

- [SymbioCellTech](symbiocelltech.md)